|
| 37971722 | Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. | JAMA Oncol | 2024 |
| 38079157 | Personal Social Networks and Care-Seeking for Head and Neck Cancer: A Qualitative Study. | Otolaryngol Head Neck Surg | 2024 |
| 36747644 | Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. | bioRxiv | 2023 |
| 37837735 | Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study. | Oral Oncol | 2023 |
| 37683037 | Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. | Sci Immunol | 2023 |
| 37087370 | Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. | Lancet Digit Health | 2023 |
| 36949070 | Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. | Nat Commun | 2023 |
| 36990508 | Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment. | J Immunother Cancer | 2023 |
| 37014021 | Endoscopic endonasal transclival approach for a ventral brainstem epidermoid cyst: illustrative case. | J Neurosurg Case Lessons | 2023 |
| 37311054 | Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma. | Cancer Res | 2023 |
| 37463106 | SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. | Cell Rep | 2023 |
| 34154446 | Assessment of Preoperative Functional Status Prior to Major Head and Neck Surgery: A Pilot Study. | Otolaryngol Head Neck Surg | 2022 |
| 35803260 | Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. | Cell | 2022 |
| 35705032 | YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4. | Cell Rep | 2022 |
| 35820346 | The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. | Oral Oncol | 2022 |
| 35355358 | Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. | Head Neck | 2022 |
| 36544971 | Virtual planning and 3D-printed guides for mandibular reconstruction: Factors impacting accuracy. | Laryngoscope Investig Otolaryngol | 2022 |
| 36875716 | Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. | Cancer Res Commun | 2022 |
| 36066413 | MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. | Cancer Res | 2022 |
| 35990387 | Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer. | Curr Otorhinolaryngol Rep | 2022 |
| 36357512 | Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens. | Nat Biomed Eng | 2022 |
| 36384079 | Accuracy and outcomes of virtual surgical planning and 3D-printed guides for osseous free flap reconstruction of mandibular osteoradionecrosis. | Oral Oncol | 2022 |
| 36301568 | Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 35256551 | Preoperative immunotherapy for head and neck cancers: state of art. | Curr Opin Oncol | 2022 |
| 34879175 | Imaging features, therapies, and outcomes of fibrosing inflammatory pseudotumor of the nasopharynx: A systematic review. | J Neuroimaging | 2022 |
| 35058328 | Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. | J Immunother Cancer | 2022 |
| 35262677 | Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. | Clin Cancer Res | 2022 |
| 35050348 | Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 35262203 | Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer. | Int J Cancer | 2022 |
| 34667025 | Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. | Clin Cancer Res | 2022 |
| 34534350 | TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. | Nucleic Acids Res | 2022 |
| 33355594 | Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. | JAMA Oncol | 2021 |
| 36860910 | Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. | Cancer Res Commun | 2021 |
| 33547198 | Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. | Clin Cancer Res | 2021 |
| 33643653 | Tumor-associated neutrophils (TANs) in human carcinoma-draining lymph nodes: a novel TAN compartment. | Clin Transl Immunology | 2021 |
| 34408919 | Integrating CD4<sup>+</sup> T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. | Oncoimmunology | 2021 |
| 34552878 | Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. | Front Oncol | 2021 |
| 34207599 | NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. | Cancers (Basel) | 2021 |
| 33403469 | Epigenetic modulation of immunotherapy and implications in head and neck cancer. | Cancer Metastasis Rev | 2021 |
| 33368875 | Personalized cancer vaccination in head and neck cancer. | Cancer Sci | 2021 |
| 33190021 | Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. | Oral Oncol | 2021 |
| 33397681 | Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. | Clin Cancer Res | 2021 |
| 31562203 | Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer. | Clin Cancer Res | 2020 |
| 31645352 | Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. | Clin Cancer Res | 2020 |
| 32098510 | Perioperative nasal and paranasal sinus considerations in transsphenoidal surgery for pituitary disease. | Br J Neurosurg | 2020 |
| 32665297 | Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. | Clin Cancer Res | 2020 |
| 32852531 | Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32493985 | GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. | Sci Rep | 2020 |
| 30510237 | Accounting for proximal variants improves neoantigen prediction. | Nat Genet | 2019 |
| 31710313 | Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. | J Clin Invest | 2019 |